Multivariate analysis of factors associated with overall mortality in patients undergoing myeloablative or reduced intensity/nonmyeloablative unrelated donor PBSC transplantation
| Variable . | n . | RR (95% CI) . | P . |
|---|---|---|---|
| Myeloablative | |||
| HLA matching status | < .001 | ||
| Well-matched | 352 | 1.00 | |
| Partially matched | 169 | 1.11 (0.89-1.40) | .351 |
| Mismatched | 78 | 1.84 (1.38-2.44) | < .001 |
| CD34+ cells dose, ×106/kg | .024 | ||
| 4.5 or less | 138 | 1.00 | |
| More than 4.5 | 289 | 0.75 (0.58-0.96) | .021 |
| Missing | 172 | 0.97 (0.74-1.27) | .808 |
| Karnofsky score | < .001 | ||
| 90-100 | 363 | 1.00 | |
| 10-80 | 180 | 1.79 (1.43-2.23) | < .001 |
| Missing | 56 | 0.94 (0.64-1.39) | .775 |
| GVHD prophylaxis | |||
| CsA-based | 342 | 1.00 | |
| FK506-based | 257 | 1.37 (1.12-1.67) | .002 |
| Donor/recipient CMV status | .007 | ||
| Negative/negative | 186 | 1.00 | |
| Negatuve/positive | 196 | 1.19 (0.93-1.53) | .173 |
| Positive/negative | 87 | 1.17 (0.84-1.62) | .357 |
| Positive/positive | 130 | 1.61 (1.23-2.12) | < .001 |
| Disease risk | < .001 | ||
| Early | 203 | 1.00 | |
| Intermediate | 210 | 1.32 (1.03-1.69) | .029 |
| Advanced | 186 | 1.74 (1.35-2.24) | < .001 |
| Reduced intensity/nonmyeloablative | |||
| CD34+ cells dose, ×106/kg | .024 | ||
| 4.5 or less | 80 | 1.00 | |
| More than 4.5 | 156 | 0.66 (0.48-0.91) | .010 |
| Missing | 85 | 0.67 (0.47-0.96) | .031 |
| Disease risk | < .001 | ||
| Early | 115 | 1.00 | |
| Intermediate | 110 | 1.17 (0.84-1.63) | .355 |
| Advanced | 96 | 1.85 (1.33-2.56) | < .001 |
| Variable . | n . | RR (95% CI) . | P . |
|---|---|---|---|
| Myeloablative | |||
| HLA matching status | < .001 | ||
| Well-matched | 352 | 1.00 | |
| Partially matched | 169 | 1.11 (0.89-1.40) | .351 |
| Mismatched | 78 | 1.84 (1.38-2.44) | < .001 |
| CD34+ cells dose, ×106/kg | .024 | ||
| 4.5 or less | 138 | 1.00 | |
| More than 4.5 | 289 | 0.75 (0.58-0.96) | .021 |
| Missing | 172 | 0.97 (0.74-1.27) | .808 |
| Karnofsky score | < .001 | ||
| 90-100 | 363 | 1.00 | |
| 10-80 | 180 | 1.79 (1.43-2.23) | < .001 |
| Missing | 56 | 0.94 (0.64-1.39) | .775 |
| GVHD prophylaxis | |||
| CsA-based | 342 | 1.00 | |
| FK506-based | 257 | 1.37 (1.12-1.67) | .002 |
| Donor/recipient CMV status | .007 | ||
| Negative/negative | 186 | 1.00 | |
| Negatuve/positive | 196 | 1.19 (0.93-1.53) | .173 |
| Positive/negative | 87 | 1.17 (0.84-1.62) | .357 |
| Positive/positive | 130 | 1.61 (1.23-2.12) | < .001 |
| Disease risk | < .001 | ||
| Early | 203 | 1.00 | |
| Intermediate | 210 | 1.32 (1.03-1.69) | .029 |
| Advanced | 186 | 1.74 (1.35-2.24) | < .001 |
| Reduced intensity/nonmyeloablative | |||
| CD34+ cells dose, ×106/kg | .024 | ||
| 4.5 or less | 80 | 1.00 | |
| More than 4.5 | 156 | 0.66 (0.48-0.91) | .010 |
| Missing | 85 | 0.67 (0.47-0.96) | .031 |
| Disease risk | < .001 | ||
| Early | 115 | 1.00 | |
| Intermediate | 110 | 1.17 (0.84-1.63) | .355 |
| Advanced | 96 | 1.85 (1.33-2.56) | < .001 |